The respiratory syncytial virus treatment market was valued at USD 2.18 Billion in 2025 and is expected to grow at a CAGR of 14.70%, reaching USD 8.59 Billion by 2035. The market growth is driven by the increasing RSV infection rates and growing approval of monoclonal antibody-based treatments across the 8 major markets. The market is further driven by rising awareness, advanced antivirals, and increasing infant RSV hospitalizations. Expanding R&D and the launch of long-acting preventive therapies are expected to support market expansion.
Base Year
Historical Period
Forecast Period
In June 2025, Moderna received U.S. FDA approval to expand mRESVIA’s use to adults aged 18–59 at increased risk for RSV, a move expected to significantly accelerate the market growth during the forecast period.
One of the major market trends includes the development of combination vaccines for respiratory infections. For instance, in February 2024, AstraZeneca acquired Icosavax to advance IVX-A12, a first-in-class RSV-hMPV vaccine.
In July 2024, the UK announced the world’s first national RSV vaccination programme for both infants and elderly adults, a move expected to significantly drive market growth by reducing hospitalizations and boosting vaccine demand.
Respiratory syncytial virus (RSV) treatment is evolving with improved therapies addressing severe infections in vulnerable populations, including infants and older adults. The market is witnessing significant growth, fueled by increasing RSV incidence, expanding healthcare access, and rising investment in advanced biologics. Enhanced diagnostic capabilities and seasonal immunization strategies are further driving demand. Key players are focusing on innovative monoclonal antibodies and antiviral drugs to strengthen their pipeline and meet global healthcare needs. The market was valued at USD 2.18 Billion in 2025, with strong growth prospects anticipated over the forecast period.
Rising Hospitalization Rates to Accelerate the Market Growth
The increasing burden of respiratory syncytial virus (RSV)-related hospitalizations, especially among vulnerable populations, is a key driver of market growth. According to the National Foundation for Infectious Diseases, RSV remains the leading cause of hospitalization in U.S. children under one year of age, accounting for 58,000–80,000 annual hospital stays in children under five. Additionally, RSV is increasingly recognized as a serious health concern among older adults, causing up to 160,000 hospitalizations annually. This rising disease burden significantly propels demand for effective RSV treatments, accelerating market expansion.
Some of the trends include the growing adoption of long-acting monoclonal antibodies and an increase in clinical trials led by innovative biopharmaceutical companies.
Rising Adoption of Long-Acting Monoclonal Antibodies Set to Boost RSV Treatment Market Value
The market is experiencing a shift towards the development and adoption of long-acting monoclonal antibodies for infant protection. For instance, in June 2025, the U.S. Food and Drug Administration approved Merck’s ENFLONSIA™ (clesrovimab-cfor), a single-dose monoclonal antibody for the prevention of RSV lower respiratory tract disease in infants. Backed by clinical data showing a 60.5% reduction in RSV-related infections and an 84.3% decrease in hospitalizations, this innovation marks a significant step in enhancing pediatric RSV prevention. Such developments are expected to drive considerable growth in the RSV treatment market.
Rising Clinical Trials to Meet the Increasing Respiratory Syncytial Virus Treatment Market Demand
The surge in clinical trials led by pharmaceutical companies is shaping the market landscape. In January 2025, Japan-based Shionogi & Co., Ltd. announced successful Phase 2 trial results for its novel oral antiviral candidate S-337395, developed in partnership with UBE Corporation. The candidate achieved its primary endpoint, showing an 88.94% reduction in viral load and favorable safety outcomes. This momentum is expected to enhance innovation and drive significant growth in the market.
Segmentation Based on Age Group to Witness Substantial Growth
The market includes various age groups, including pediatric, adult, and geriatric populations, each requiring tailored treatment approaches based on risk and disease severity. Among these, the pediatric segment is expected to hold a significant share in the market, due to the high incidence of RSV infections in infants and young children. In July 2023, the FDA approved Beyfortus (nirsevimab‑alip) for use in infants born during or entering their first RSV season and for children up to 24 months who remain vulnerable in their second season. Clinical trials demonstrated a 70–75% reduction in medically attended RSV lower respiratory tract infections. These compelling results underscore the urgent need for pediatric RSV prevention and position this age group as a key driver of market growth, supported by rising awareness, regulatory approvals, and advances in monoclonal antibody therapies.
The market is divided into regions such as the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to dominate, driven by a high disease burden, advanced healthcare infrastructure, and active regulatory engagement. In July 2025, the U.S. Food and Drug Administration accepted GSK’s application to expand the use of its RSV vaccine, Arexvy, to adults aged 18–49 at increased risk. Supported by Phase IIIb data, a regulatory decision is anticipated in the first half of 2026, reinforcing U.S. leadership in RSV treatment. Such developments are expected to accelerate innovation and access in RSV treatment across the region.
The respiratory syncytial virus treatment market research report by Expert Market Research provides an in-depth analysis of the competitive landscape, offering key insights into patent filings, grants, funding trends, investments, and strategic initiatives by major players. It tracks recent investments, mergers, acquisitions, and partnerships that showcase the market's growth trajectory. Additionally, the report details strategic activities by leading companies, including regional expansions, adoption of new technologies, and efforts to enhance capacity, helping stakeholders better understand the market dynamics and positions of key industry players. Some of the leading players are as follows:
AstraZeneca plc, a leader in respiratory care, is actively addressing respiratory syncytial virus (RSV), a major contributor to childhood respiratory infections. Through ongoing research and its collaboration with Sanofi, the company aims to enhance prevention and management strategies for RSV. While not directly involved in functional mushrooms, AstraZeneca’s focus on immune therapies aligns with broader market trends in immunity enhancement.
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, is known for developing oral antiviral treatments for severe viral infections, including respiratory syncytial virus (RSV). Its earlier developments and its proprietary nucleotide prodrug platform highlight its broader commitment to targeting ssRNA viruses, such as RSV. The company continues to explore therapeutic opportunities in the landscape of respiratory virus treatments.
Enanta Pharmaceuticals, Inc. is a biotechnology company focused on developing small-molecule drugs for viral infections. In the respiratory syncytial virus (RSV) treatment market, the company is advancing novel antiviral therapies to address the significant global burden of RSV, particularly among infants, older adults, and immunocompromised individuals. Enanta's involvement reflects its commitment to addressing the unmet need for effective and safe RSV treatments beyond the current limited options.
F. Hoffmann-La Roche Ltd. plays a significant role in the respiratory syncytial virus (RSV) treatment market through its cobas® Influenza A/B & RSV test. Designed for use on the cobas® liat system, this nucleic acid test enables rapid and accurate detection of RSV, along with influenza A and B, within 20 minutes. Especially valuable for vulnerable populations such as children under four and adults over 65, the test supports timely clinical decisions and infection control. Roche’s commitment to speed and precision at the point of care enhances its contribution to respiratory virus diagnostics.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include AbbVie Inc., Celltrion Inc., Gilead Sciences, Inc., and GlaxoSmithKline PLC.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Market Breakup by Route of Administration
Market Breakup by Age Group
Market Breakup by Distribution Channel
Market Breakup by Region
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Age Group |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share